Unicycive Therapeutics Inc. Common Stock (UNCY)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is offering this clinical-stage kidney company at $3.73 a share, a $103.9 million market value as of the close on 2026-10-13. As a Graham-style investor, I start with the record: in fiscal 2023, the company reported revenue of $675,000 and a net loss of $30.5 million, or diluted EPS of -$1.28. In fiscal 2024, there was no revenue in the filed figures, a net loss of $36.7 million, and diluted EPS of -$5.65. Fiscal 2025 showed no revenue, a net loss of $26.6 million, and diluted EPS of -$1.67. In fiscal Q1 2026, the quarter ended 2026-03-31, the net loss was $12.8 million; in fiscal Q2 2026, the quarter ended 2026-06-30, it was $1.7 million. That latest quarter is better, but one quarter does not make a business. The balance sheet has low leverage—D/E of 0.01—but that is not enough. Trailing free cash flow is -$27.8 million, a -26.8% FCF yield, and FairStock's Piotroski F-Score is 2/9 and Altman Z-Score 1.43, both warning of financial fragility. At the 2026-10-13 close, FairStock calculations show P/E of -2.13 and P/B of 1.95; ROE is -101.07% and ROCE is -40.59%. Without revenue or profits, there is no meaningful earnings multiple and no clear moat; the value depends on clinical and regulatory success for oxylanthanum carbonate and UNI-494. I prefer businesses that produce cash and have durable competitive advantages. This one may have a promising kidney-disease niche, but until it proves commercial viability, the equity is speculative, and the provided 73.29% profit growth figure does not change the absence of revenue.

In plain English: Unicycive Therapeutics is a small drug developer focused on kidney diseases. The business looks weak today: it has no recent product sales and is losing money, though its net loss shrank to $1.7 million in the quarter ended June 30, 2026, from $12.8 million in the prior quarter. At $3.73 on October 13, 2026, the price looks expensive against the company's current earnings because there are none, even though it carries very little debt.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer